Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 824 results for "eisai"

Unichem gets USFDA nod for its Donepezil hydrochloride tabs

Unichem receives approval for donepezil hydrochloride tablets

The product, which is generic version of Eisai's Aricept, is used to improve cognition and behaviour of people with Alzheimer's BS B2B Bureau | Mumbai June 24, 2016 Last Updated at 14:02 IST Unichem Laboratories Limited has received ANDA approval ... Business Standard India, 12 hours ago

34 images for eisai

BioSpace, 2 days ago, 1 day ago
BioSpace, 1 week ago
Yahoo! Singapore, 1 week ago
Forwardgeek, 1 week ago
APN News, 1 week ago
APN News, 1 week ago
APN News, 1 week ago
APN News, 1 week ago
APN News, 1 week ago

Eisai Inc. To Host On June 29, 2016 In New York City

/PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it will host a Scientific Day on June 29, 2016 from 9:00 a.m. EDT to 12:45 p.m. EDT in New York City , and will be simultaneously streamed as a ...
 BioSpace2 days ago Eisai Inc. to Host Scientific Day on June 29, 2016 in New York City  WorldNetDaily2 days ago Eisai launches U.S. Fycompa oral suspension for patients with swallowing problems  FiercePharma3 days ago Eisai Inc to Host Scientific Day on June 29 2016 in New York City  Pharma Focus Asia1 day ago
Pharma Business International

AbbVie and EA Pharma to co-promote Humira for gastrointestinal diseases

AbbVie, along with EA Pharma, a subsidiary of Japanese pharmaceutical company Eisai, will begin the co-promotion of fully human anti-TNF-alpha monoclonal antibody Humira for indications in the field of gastrointestinal diseases. Humira is a fully ...
 Pharmaceutical Technology3 weeks ago 2016 Japan Pharma Outlook - growth drivers of 12 major Japanese biopharma companies  Before It's News2 days ago

Eisai Inc. v. Sanofi Aventus U.S. LLC

| Choose Existing Folder ]]> Your (Article, Chart, Blog) was successfully saved to your folder My Default Folder Don't forget you can visit My Briefcase to manage your folders at
 New Jersey Law Journal3 weeks ago

New Data for Eisai's Halaven® (eribulin) and Lenvima® (lenvatinib) in Hard to Treat Cancers will be Presented at Forthcoming American Society of Clinical Oncology (ASCO) Meeting

ASCO invites six abstracts on new Halaven® (eribulin) data in liposarcoma and solid tumours, and new lenvatinib data in thyroid cancers and in renal cell carcinoma Six abstracts that feature new study results in hard to treat cancers ...
 Sys-Con India1 month ago
Money Control

Dr Reddy's ties up with Eisai

Hyderabad-based Dr Reddy's Laboratories (DRL) has entered into a licensing agreement with Eisai by which it will get exclusive development and commercialisation rights (excluding Japan and Asia) for Eisai's investigational anti-cancer agent E7777. The company ...
 The Telegraph2 months ago Dr. Reddy's inks licensing pact with Japan's Eisai  Myiris2 months ago Dr Reddy’s, Japan’s Eisai in licensing pact for anti-cancer agent  Business Line2 months ago Dr. Reddy's acquires E7777s rights from Eisai  India Infoline2 months ago

Dr. Reddy’s in licensing agreement with Eisai

To develop, commercialise the Japanese firm’s investigational anticancer agent E7777
 The Hindu2 months ago Dr Reddy's inks pact with Japan's Eisai for developing anticancer agent  DNA2 months ago

Global Insomnia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Eisai, Evotec, Novartis - Research and Markets

Research and Markets has announced the addition of the "Insomnia - Pipeline Review, H1 2016" report to their offering. Research and Markets has announced the addition of the "Insomnia - Pipeline Review, H1 2016" report to their offering. The ...
 Minyanville2 weeks ago 2016 Insomnia Pipeline Market Analysis  Before It's News2 weeks ago New Market Research Report: Orexin Receptor Type 2 - Pipeline Review, H1 2016  Digital Journal5 hours ago Global Myelodysplastic Syndrome Pipeline Report 2016 - Pipeline Review of 92 Therapeutic Companies - Research and Markets  4 Traders11 hours ago

AbbVie, Eisai Company, And Obtain Additional Approval For New Dosing Regimen Of Fully Human Anti-TNF Monoclonal Antibody Humira In Patients With Crohn's Disease

- (ACN Newswire) - AbbVie GK (Headquarters: Tokyo, President: James Feliciano, "AbbVie"), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, "EA ...
 BioSpace4 days ago AbbVie, Eisai and EA Pharma receive additional approval for new Humira dosing regimen  Pharmaceutical Technology2 days ago EISAI : AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease  4 Traders4 days ago AbbVie, Eisai, EA Pharma obtain additional approval for...  Bio Spectrum Asia3 days ago

Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program

- Incorporated (NASDAQ: CORT) Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven®) to treat triple-negative breast cancer (TNBC) indicate combination is active; final results expected in mid-2016 First ...
 Yahoo! Finance3 weeks ago Corcept Therapeutics Inc. Provides Update Of Progress In Cortisol Modulation Oncology Program  BioSpace2 weeks ago CORCEPT THERAPEUTICS : Provides Update of Progress in Cortisol Modulation Oncology Program  4 Traders3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
Get updated on latest news & your favorite topics right in your inbox!
More     Less